Convection-enhanced delivery of macromolecules in the brain.
PDF (1.3M)
Journal: 1994/April - Proceedings of the National Academy of Sciences of the United States of America
ISSN: 0027-8424
PUBMED: 8134351
Abstract:
For many compounds (neurotrophic factors, antibodies, growth factors, genetic vectors, enzymes) slow diffusion in the brain severely limits drug distribution and effect after direct drug administration into brain parenchyma. We investigated convection as a means to enhance the distribution of the large and small molecules 111In-labeled transferrin (111In-Tf; M(r), 80,000) and [14C]sucrose (M(r), 359) over centimeter distances by maintaining a pressure gradient during interstitial infusion into white matter to generate bulk flow through the brain interstitium. The volume of distribution (Vd) containing>> or = 1% concentration of infusion solution increased linearly with the infusion volume (Vi) for 111In-Tf(Vd/Vi, 6:1) and [14C]sucrose (Vd/Vi, 13:1). Twenty-four hours after infusion, the distribution of 111In-Tf was increased and more homogeneous, and penetration into gray matter had occurred. By using convection to supplement simple diffusion, enhanced distribution of large and small molecules can be obtained in the brain while achieving drug concentrations orders of magnitude greater than systemic levels.
Open in
PUBMED | PMC | Google Scholar | Wikipedia
Relations:
Content
Citations
(371)
References
(37)
Clinical trials
(1)
Drugs
(1)
Chemicals
(2)
Organisms
(2)
Processes
(3)
Anatomy
(1)
Affiliates
(1)
Similar articles
Articles by the same authors
Discussion board
Proc Natl Acad Sci U S A 91(6): 2076-2080
PMID: 8134351

Convection-enhanced delivery of macromolecules in the brain.

Abstract

For many compounds (neurotrophic factors, antibodies, growth factors, genetic vectors, enzymes) slow diffusion in the brain severely limits drug distribution and effect after direct drug administration into brain parenchyma. We investigated convection as a means to enhance the distribution of the large and small molecules 111In-labeled transferrin (111In-Tf; M(r), 80,000) and [14C]sucrose (M(r), 359) over centimeter distances by maintaining a pressure gradient during interstitial infusion into white matter to generate bulk flow through the brain interstitium. The volume of distribution (Vd) containing > or = 1% concentration of infusion solution increased linearly with the infusion volume (Vi) for 111In-Tf(Vd/Vi, 6:1) and [14C]sucrose (Vd/Vi, 13:1). Twenty-four hours after infusion, the distribution of 111In-Tf was increased and more homogeneous, and penetration into gray matter had occurred. By using convection to supplement simple diffusion, enhanced distribution of large and small molecules can be obtained in the brain while achieving drug concentrations orders of magnitude greater than systemic levels.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.3M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
icon of scanned page 2076
2076
icon of scanned page 2077
2077
icon of scanned page 2078
2078
icon of scanned page 2079
2079
icon of scanned page 2080
2080

Images in this article

Image
Image
on p.2078
Image
Image
on p.2079
Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Oldendorf WH. Lipid solubility and drug penetration of the blood brain barrier. Proc Soc Exp Biol Med. 1974 Dec;147(3):813–815. [PubMed] [Google Scholar]
  • Jain RK. Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J Natl Cancer Inst. 1989 Apr 19;81(8):570–576. [PubMed] [Google Scholar]
  • Obbens EA, Feun LG, Leavens ME, Savaraj N, Stewart DJ, Gutterman JU. Phase I clinical trial of intralesional or intraventricular leukocyte interferon for intracranial malignancies. J Neurooncol. 1985;3(1):61–67. [PubMed] [Google Scholar]
  • Zovickian J, Johnson VG, Youle RJ. Potent and specific killing of human malignant brain tumor cells by an anti-transferrin receptor antibody-ricin immunotoxin. J Neurosurg. 1987 Jun;66(6):850–861. [PubMed] [Google Scholar]
  • Harbaugh RE. Novel CNS-directed drug delivery systems in Alzheimer's disease and other neurological disorders. Neurobiol Aging. 1989 Sep-Oct;10(5):623–629. [PubMed] [Google Scholar]
  • Blasberg RG, Patlak C, Fenstermacher JD. Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion. J Pharmacol Exp Ther. 1975 Oct;195(1):73–83. [PubMed] [Google Scholar]
  • Dedrick RL, Flessner MF. Pharmacokinetic considerations on monoclonal antibodies. Prog Clin Biol Res. 1989;288:429–438. [PubMed] [Google Scholar]
  • Rubin RC, Ommaya AK, Henderson ES, Bering EA, Rall DP. Cerebrospinal fluid perfusion for central nervous system neoplasms. Neurology. 1966 Jul;16(7):680–692. [PubMed] [Google Scholar]
  • Ringkjob R. Treatment of intracranial gliomas and metastatic carcinomas by local application of cytostatic agents. Acta Neurol Scand. 1968;44(3):318–322. [PubMed] [Google Scholar]
  • Garfield J, Dayan AD. Postoperative intracavitary chemotherapy of malignant gliomas. A preliminary study using methotrexate. J Neurosurg. 1973 Sep;39(3):315–322. [PubMed] [Google Scholar]
  • Bosch DA, Hindmarsch T, Larsson S, Backlund EO. Intraneoplastic administration of bleomycin in intracerebral gliomas: a pilot study. Acta Neurochir Suppl (Wien) 1980;30:441–444. [PubMed] [Google Scholar]
  • Morantz RA, Kimler BF, Vats TS, Henderson SD. Bleomycin and brain tumors. A review. J Neurooncol. 1983;1(3):249–255. [PubMed] [Google Scholar]
  • Penn RD, Kroin JS, Harris JE, Chiu KM, Braun DP. Chronic intratumoral chemotherapy of a rat tumor with cisplatin and fluorouracil. Appl Neurophysiol. 1983;46(1-4):240–244. [PubMed] [Google Scholar]
  • Bouvier G, Penn RD, Kroin JS, Beique R, Guerard MJ. Direct delivery of medication into a brain tumor through multiple chronically implanted catheters. Neurosurgery. 1987 Feb;20(2):286–291. [PubMed] [Google Scholar]
  • Brem H, Mahaley MS, Jr, Vick NA, Black KL, Schold SC, Jr, Burger PC, Friedman AH, Ciric IS, Eller TW, Cozzens JW, et al. Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg. 1991 Mar;74(3):441–446. [PubMed] [Google Scholar]
  • Nierenberg D, Harbaugh R, Maurer LH, Reeder T, Scott G, Fratkin J, Newman E. Continuous intratumoral infusion of methotrexate for recurrent glioblastoma: a pilot study. Neurosurgery. 1991 May;28(5):752–761. [PubMed] [Google Scholar]
  • Garfield J, Dayan AD, Weller RO. Postoperative intracavitary chemotherapy of malignant supratentorial astrocytomas using BCNU. Clin Oncol. 1975 Sep;1(3):213–222. [PubMed] [Google Scholar]
  • Kroin JS, Penn RD. Intracerebral chemotherapy: chronic microinfusion of cisplatin. Neurosurgery. 1982 Mar;10(3):349–354. [PubMed] [Google Scholar]
  • Merchant RE, Merchant LH, Cook SH, McVicar DW, Young HF. Intralesional infusion of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) for the treatment of patients with malignant brain tumor. Neurosurgery. 1988 Dec;23(6):725–732. [PubMed] [Google Scholar]
  • Barba D, Saris SC, Holder C, Rosenberg SA, Oldfield EH. Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg. 1989 Feb;70(2):175–182. [PubMed] [Google Scholar]
  • Sendelbeck SL, Urquhart J. Spatial distribution of dopamine, methotrexate and antipyrine during continuous intracerebral microperfusion. Brain Res. 1985 Mar 4;328(2):251–258. [PubMed] [Google Scholar]
  • SCHANTZ EJ, LAUFFER MA. Diffusion measurements in agar gel. Biochemistry. 1962 Jul;1:658–663. [PubMed] [Google Scholar]
  • Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res. 1987 Jun 15;47(12):3039–3051. [PubMed] [Google Scholar]
  • Morrison PF, Dedrick RL. Transport of cisplatin in rat brain following microinfusion: an analysis. J Pharm Sci. 1986 Feb;75(2):120–128. [PubMed] [Google Scholar]
  • Rosenberg GA, Kyner WT, Estrada E. Bulk flow of brain interstitial fluid under normal and hyperosmolar conditions. Am J Physiol. 1980 Jan;238(1):F42–F49. [PubMed] [Google Scholar]
  • Reulen HJ, Graham R, Spatz M, Klatzo I. Role of pressure gradients and bulk flow in dynamics of vasogenic brain edema. J Neurosurg. 1977 Jan;46(1):24–35. [PubMed] [Google Scholar]
  • Ohata K, Marmarou A, Povlishock JT. An immunocytochemical study of protein clearance in brain infusion edema. Acta Neuropathol. 1990;81(2):162–177. [PubMed] [Google Scholar]
  • Ohata K, Marmarou A. Clearance of brain edema and macromolecules through the cortical extracellular space. J Neurosurg. 1992 Sep;77(3):387–396. [PubMed] [Google Scholar]
  • Cserr HF, Ostrach LH. Bulk flow of interstitial fluid after intracranial injection of blue dextran 2000. Exp Neurol. 1974 Oct;45(1):50–60. [PubMed] [Google Scholar]
  • Blasberg RG, Gazendam J, Patlak CS, Fenstermacher JD. Quantitative autoradiographic studies of brain edema and a comparison of multi-isotope autoradiographic techniques. Adv Neurol. 1980;28:255–270. [PubMed] [Google Scholar]
  • Lewellen TK, Graham MM, Spence AM. Quantitative autoradiography using a personal computer. J Nucl Med. 1986 Apr;27(4):549–554. [PubMed] [Google Scholar]
  • Ito U, Reulen HJ, Tomita H, Ikeda J, Saito J, Maehara T. A computed tomography study on formation, propagation, and resolution of edema fluid in metastatic brain tumors. Adv Neurol. 1990;52:459–468. [PubMed] [Google Scholar]
  • Patlak CS, Fenstermacher JD. Measurements of dog blood-brain transfer constants by ventriculocisternal perfusion. Am J Physiol. 1975 Oct;229(4):877–884. [PubMed] [Google Scholar]
  • Hill JM, Ruff MR, Weber RJ, Pert CB. Transferrin receptors in rat brain: neuropeptide-like pattern and relationship to iron distribution. Proc Natl Acad Sci U S A. 1985 Jul;82(13):4553–4557.[PMC free article] [PubMed] [Google Scholar]
  • Karin M, Mintz B. Receptor-mediated endocytosis of transferrin in developmentally totipotent mouse teratocarcinoma stem cells. J Biol Chem. 1981 Apr 10;256(7):3245–3252. [PubMed] [Google Scholar]
  • Rapoport SI, Thompson HK. Osmotic opening of the blood-brain barrier in the monkey without associated neurological deficits. Science. 1973 Jun 1;180(4089):971–971. [PubMed] [Google Scholar]
  • Hossmann KA, Blöink M, Wilmes F, Wechsler W. Experimental peritumoral edema of the cat brain. Adv Neurol. 1980;28:323–340. [PubMed] [Google Scholar]
Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892.
Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892.
Copyright notice
Abstract
For many compounds (neurotrophic factors, antibodies, growth factors, genetic vectors, enzymes) slow diffusion in the brain severely limits drug distribution and effect after direct drug administration into brain parenchyma. We investigated convection as a means to enhance the distribution of the large and small molecules 111In-labeled transferrin (111In-Tf; M(r), 80,000) and [14C]sucrose (M(r), 359) over centimeter distances by maintaining a pressure gradient during interstitial infusion into white matter to generate bulk flow through the brain interstitium. The volume of distribution (Vd) containing > or = 1% concentration of infusion solution increased linearly with the infusion volume (Vi) for 111In-Tf(Vd/Vi, 6:1) and [14C]sucrose (Vd/Vi, 13:1). Twenty-four hours after infusion, the distribution of 111In-Tf was increased and more homogeneous, and penetration into gray matter had occurred. By using convection to supplement simple diffusion, enhanced distribution of large and small molecules can be obtained in the brain while achieving drug concentrations orders of magnitude greater than systemic levels.
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.